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Plasmepsins are a group of diverse aspartic proteases in the
malaria parasite Plasmodium. Their functions are strikingly
multifaceted, ranging from hemoglobin degradation to secre-
tory organelle protein processing for egress, invasion, and effec-
tor export. Some, particularly the digestive vacuole plasmepsins,
have been extensively characterized, whereas others, such as the
transmission-stage plasmepsins, are minimally understood.
Some (e.g. plasmepsin V) have exquisite cleavage sequence spec-
ificity; others are fairly promiscuous. Some have canonical pep-
sin-like aspartic protease features, whereas others have unusual
attributes, including the nepenthesin loop of plasmepsin V and a
histidine in place of a catalytic aspartate in plasmepsin III. We
have learned much about the functioning of these enzymes, but
more remains to be discovered about their cellular roles and
even their mechanisms of action. Their importance in many key
aspects of parasite biology makes them intriguing targets for
antimalarial chemotherapy. Further consideration of their
characteristics suggests that some are more viable drug tar-
gets than others. Indeed, inhibitors of invasion and egress
offer hope for a desperately needed new drug to combat this
nefarious organism.
Malaria is caused by protozoan organisms of the genus Plas-
modium. The disease is transmitted by infected female Anoph-
eles mosquitos, which inject salivary gland sporozoites into the
skin during bloodfeeding. These sporozoites make their way to
the liver, replicate, and differentiate into infective merozoites.
The merozoites egress into the bloodstream, where they invade
red blood cells (RBCs) and set up a continuous intraerythro-
cytic cycle that amplifies their population, often to overwhelm-
ing numbers. Some differentiate into sexual-stage parasites, to
be taken up by the next mosquito and develop in the mosquito
midgut, ultimately migrating to the salivary glands for spread to
a new victim (Fig. 1).
Aspartic proteases called plasmepsins (Plasmodium pepsins,
abbreviated PM) play important roles in each stage of Plasmo-
dium development. Interest in the plasmepsins began when the
digestive vacuole plasmepsins (I, II, III, and IV) were found to be
important for intraerythrocytic hemoglobin degradation (1–5).
There followed a major effort to make small-molecule inhibi-
tors to these enzymes, especially PM II, the easiest to express
and the first to have a crystal structure (6, 7). A poor correlation
between ability of a compound to kill parasites and potency
against isolated enzyme (8) suggested that digestive vacuole
plasmepsin inhibition was not the mode of parasite killing
for these molecules. This ultimately led to the realization
that there must be other targets, likely other aspartic pro-
teases, whose inhibition is responsible for the antiplasmodial
properties. The search for these targets has uncovered myr-
iad functions for these enzymes. Plasmepsins are involved in
bulk protein degradation, secretory protein maturation,
egress, invasion, endothelial adherence, and perhaps other
processes. A number have been the subject of serious efforts
as targets for drug development.
Plasmepsins (Fig. 2) belong to an ancient family of aspartic
proteases—the A1 or pepsin-like family—that is widespread
throughout eukaryotes. Among the 10 plasmepsins, the most
closely related are the digestive vacuolar plasmepsins, PM I–IV.
These proteases are spread across just 16 kilobases of chromo-
some 14 and share 50 –70% amino acid identity. Outside of
P. falciparum and related primate-infecting species, these pro-
teases are represented by a single plasmepsin, called PM IV in
Plasmodium and ASP1 in the related apicomplexan Toxo-
plasma gondii (9). PM V is the most diverged plasmepsin, shar-
ing 19 –23% amino acid identity with the other plasmepsins. Its
structure is bolstered by seven disulfide bonds (compared with
two in PM I–IV), bringing it into a separate aspartic protease
subfamily from the other plasmepsins—subfamily A1B, with
type member Nep1 of the pitcher plant Nepenthesia (10). Other
apicomplexans also have a single PM V ortholog (ASP5 in Tox-
oplasma gondii), except for cryptosporidia, which have three
(9). Regarding transmission-stage plasmepsins, PM VI and VIII
form a clade, sharing 36% amino acid identity with each other.
Each has a little-studied ortholog in T. gondii (ASP2 and ASP4
respectively). PM VII has distant homology to PM VI and VIII
(31% identity); its uncharacterized Toxoplasma ortholog is
ASP6. PM IX and PM X share 37% amino acid identity. Al-
though the two are distinct across Plasmodium and exist on
different chromosomes, they are represented by a single T. gon-
dii aspartic protease, ASP3.
A note on nomenclature: In the literature, plasmepsins are
denoted with Roman numerals or Arabic numerals, with or
without a space before the number, and plasmepsin III is known
as histo-aspartic protease or HAP or PM III (or PMIII or PM3
or PM 3). We suggest going back to a convention initiated in
early publications of having Roman numerals after a space. We
further suggest that HAP be referred to as PM III for consis-
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tency with the other plasmepsins and because its His32 has not
been shown to be catalytic. Also, HAP is the name for a gamete
fusion protein. Using PM III allows the digestive vacuole plas-
mepsins in aggregate to be called PM I–IV without ambiguity.
An argument for the space before the Roman numeral is that
PM V is often referred to in discussions of sending proteins out
to the parasitophorous vacuolar membrane or PVM, and PMV
gets confusing in this context. These issues are ultimately for
those concerned with nomenclature to weigh in on, but in this
review, we will use our preferred convention.
There are also nonplasmepsin aspartic proteases in the
Plasmodium genome (see “Other aspartic proteases”). The
microgametocyte surface protein (MiGS) has homology to
PM V (21% amino acid identity and shared transmembrane
domain; 17–20% to other plasmepsins). Additional aspartic
proteases in the Plasmodium genome—signal peptide pepti-
dase (SPP) and DNA damage-inducible 1 (Ddi1)—are quite dis-
tinct from the plasmepsins. SPP is a presenilin-type aspartic
protease (family A22). Ddi1 (family A28) is the most diverged
from the other aspartic proteases. It possesses a single catalytic
aspartate and likely homodimerizes to complete the active site,
an unusual architecture among eukaryotic aspartic proteases
(although common to retroviral aspartic proteases).
Here, we review the state of knowledge on the plasmepsins,
noting outstanding questions in the field. This review will focus
on P. falciparum, the deadliest human malaria parasite, for
which extensive biological studies have been performed; refer-
ence to other species will be made as relevant. Study of the
Figure 1. Life cycle of the malaria parasite. Sporozoites from the salivary glands of an infected mosquito (bottom) make their way to the liver, infect
hepatocytes, replicate to thousands of infective merozoites, and bud off as merosomes that rupture into the bloodstream. The merozoites invade RBCs,
replicate, and multiply in the intraerythrocytic cycle. Some differentiate into male and female gametocytes that are taken up into the mosquito, where they
develop. In the mosquito midgut, parasites egress from the RBCs as gametes, mate to form zygotes, and differentiate into ookinetes that traverse the midgut
and become oocysts. They replicate and differentiate into sporozoites that migrate to the salivary glands, where they are ready for transmission to the next
human upon mosquito bite. Points in the life cycle at which plasmepsins are thought to function are labeled.
Figure 2. Plasmepsin phylogeny. Sequences for PMs I–X were obtained
from PlasmoDB (release 46), aligned using MUSCLE (“Multiple Sequence
Comparison by Log-Expectation”, EMBL) (189), and visualized using iTOL
(Interactive Tree of Life) (190).
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diverse plasmepsins has taught us much about the biology of
the malaria parasite and a little about the protein chemistry of
aspartic proteases and is pointing the way to exciting new inhib-
itors that are being developed as antimalarial chemotherapeu-
tic agents.
Digestive vacuole plasmepsins: Plasmepsins I–IV
Intraerythrocytic malaria parasites digest hemoglobin at a
prodigious rate (11). This catabolic process provides nutrients
for the parasite and has been proposed to maintain osmotic
balance in the host cell (11–13). Hemoglobin is ingested by
Plasmodium through an endocytic structure called the cytos-
tome, which spans the plasma membrane and the vacuolar
membrane surrounding the parasite (Fig. 3A) (14, 15). Hemo-
globin-containing vesicles pinch off and fuse with the digestive
vacuole, an acidic organelle containing 10 proteases that func-
tion in a semi-ordered pathway to degrade the hemoglobin to
small peptides and amino acids (16 –18) (Fig. 3B). Some of these
peptides are thought to be exported out of the digestive vacuole
for terminal degradation in the cytoplasm (17, 19, 20).
The degradative process may start in transport vesicles and
commences early after erythrocyte invasion (14). Heme is lib-
erated by degradation and most is sequestered as a crystalline
lattice of -hematin dimers called hemozoin (21). Some anti-
malarial drugs like chloroquine appear to function by blocking
heme sequestration, leading to toxic heme build-up (22). A net-
work of proteins implicated in the hemoglobin endocytosis pro-
cess has recently been defined and includes the artemisinin-
resistance protein Kelch13 (23). This finding has yielded a
cogent mechanistic explanation for artemisinin resistance.
Mutations in Kelch13 and other proteins cause decreased
hemoglobin ingestion and digestion, yielding less artemisinin-
activating heme (23, 24).
Discovery
Involvement of aspartic proteases in hemoglobin digestion
was suspected nearly 50 years ago from the characterization of
crude parasite extracts (25, 26). The older literature contains
numerous reports of hemoglobin-degrading acidic protease
activities in various Plasmodium species, and some were shown
to be blocked by the canonical aspartic protease inhibitor pep-
statin A (25–34). Their cellular roles remained unclear until
studies on isolated digestive vacuoles showed the ability to
degrade hemoglobin (16, 35), and protease inhibitor profiling of
hemoglobinase activity from highly purified digestive vacuoles
revealed a central role for aspartic proteases (16). Soon there-
after, two aspartic proteases (now called PM I and II) were puri-
fied from large-scale digestive vacuole preparations and shown
to cleave hemoglobin (1, 2, 36). After release of the P. falcipa-
rum genome, two more plasmepsins were shown to be present
in the digestive vacuole, PM III and PM IV (4, 5, 37).
Figure 3. Hemoglobin ingestion and digestion. A, electron micrograph of a
P. falciparum-infected erythrocyte. C, cytostome; V, vesicle; DV, digestive vac-
uole. Adapted from Ref. 16. This research was originally published in Proceed-
ings of the National Academy of Sciences of the United States of America.
Goldberg, D. E., Slater, A. F. G., Cerami, A., and Henderson, G. B. Hemoglobin
degradation in the malaria parasite Plasmodium falciparum: an ordered pro-
cess in a unique organelle. Proc. Natl. Acad. Sci. U.S.A. 1990; 87:2931–2935.
© United States National Academy of Sciences. B, semi-ordered pathway of
hemoglobin degradation. Plasmepsins and falcipains are involved in the ini-
tial steps of catabolism and are partially redundant. Falcilysin recognizes oli-
gopeptides. DPAP1 cleaves two residues off of the N terminus of hemoglobin
fragments. Aminopeptidases finish the digestion, resulting in free amino
acids. Heme is liberated during the initial steps of proteolysis; most is seques-
tered in the digestive vacuole as hemozoin. C, plasmepsin targeting pathway
follows the hemoglobin internalization route. Plasmepsins are made in the ER
and traverse the secretory system as type II integral membrane protein pre-
cursors (ball and stick). They traffic to the cytostome, a hemoglobin ingestion
apparatus that spans the two membranes at the parasite surface. They are
internalized with their substrate cargo (hemoglobin) and are delivered to the
digestive vacuole surface, where they are cleaved by falcipain-2. PPM, para-
site plasma membrane. Black bars, hemozoin crystals that accumulate after
heme release.
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There is extensive functional redundancy among the diges-
tive vacuole plasmepsins and between these enzymes and the
cysteine proteases called falcipains. Knockouts of individual
P. falciparum plasmepsins have minor effects on parasite
growth in culture (38 –41), whereas knockout of all four leads to
a substantial growth defect, although the knockout line is still
viable (42). Knockout of the single Plasmodium berghei diges-
tive vacuole plasmepsin yields a similar phenotype in the mouse
model (43, 44). Cysteine protease inhibitors are more potent in
the P. falciparum knockouts (38, 42), and knockouts of falci-
pain-2 are more sensitive to aspartic protease inhibitors (45),
highlighting the redundancy between the two digestive vacuole
protease families. Plasmepsins and falcipains are synergistic in
biochemical assays of hemoglobin degradation (16, 36, 46), and
cysteine/aspartic protease inhibitor synergism is observed in
culture (47, 48) as well as in a rodent malaria model (48). A final
level of redundancy is that digestive vacuole plasmepsins are
activated by falcipains, but if the falcipains are impaired, plas-
mepsins can autoactivate (49) (see below). Further proteolysis
of globin fragments by the metalloprotease falcilysin (50, 51),
dipeptidyl aminopeptidase 1 (DPAP1) (52), aminopeptidase P
(53), and aminopeptidase M1 (54) finishes the degradation pro-
cess (Fig. 3). The digestive vacuole plasmepsins have been
proposed to be in a complex with some of the downstream
proteases as well as with a heme detoxification protein (HDP) in
the digestive vacuole (55).
Curiously, recent reports have associated amplification of
PM II and PM III with resistance to the antimalarial drug pip-
eraquine in several lineages of Southeast Asian field isolates
(56 –58) Removal of these extra copies of PM II/PM III resen-
sitized parasites to piperaquine, suggesting that this amplifica-
tion contributes to the resistance phenotype (58). Additionally,
deletion of PM II or PM III from a laboratory P. falciparum
strain sensitized parasites to piperaquine in vitro (59). How-
ever, increasing PM II/PM III levels is not sufficient to impart
piperaquine resistance in laboratory strains, hinting at a more
complex picture, where interplay between PM II/PM III levels
and other constituents of a strain’s genetic background contrib-
utes to phenotypic resistance (60). Consistent with this, poly-
morphisms in the digestive vacuolar membrane transporter
PfCRT are sufficient to impart piperaquine resistance in vitro,
and parasite lines with these PfCRT mutations naturally lose
PM II/PM III amplification while retaining piperaquine resis-
tance in culture (61).
Structure and mechanism
The structures of all four P. falciparum digestive vacuole
plasmepsins and the singleton PM IV from several other species
have been elucidated (7, 62–68). Each has the typical bilobal
pepsin-family aspartic protease fold. These plasmepsins are
capable of forming dimers in crystalline form and in solution
(69, 70), although it is the monomer that has been shown to
be active. The PM III dimer has a loop from one of the sub-
units that intrudes into the second subunit active site, where
it coordinates a zinc ion via Asp215 and His32 (67). The
canonical Asp215–Thr218 hydrogen bond is disrupted by the
zinc coordination.
PM I, II, and IV appear to function as typical aspartic pro-
teases, with their two aspartates participating in acid-base cat-
alytic activation of a water molecule through a tetrahedral tran-
sition state (71, 72), but in contrast, the mechanism of PM III
(Fig. 4A) is not fully understood (66). In PM III, Asp215 appears
to function as a catalytic base, activating the water to form the
hydrolytic nucleophile (67). It is not clear whether His32 is
involved in catalysis. It could be the catalytic acid for resolution
of the tetrahedral intermediate typical of aspartic protease
action, in analogy to the standard aspartate in this position. The
positioning of the statine hydroxyl between Asp215 and His32 in
the transition-state inhibitor pepstatin-bound structure is sup-
portive of this concept (67). A H32A mutant of recombinant
PM III retained activity, however (73). It has been suggested
that PM III could be a serine protease, using Ser35 as the nucleo-
phile (74), but a S35A mutant retained activity (73), and the
pepstatin active site interactions in the structure look more
consistent with an aspartic protease mechanism (67). Concern-
ing the possibility that it could be a zinc metalloprotease, native
enzyme was not inhibited by EDTA (5), and only the dimeric
Figure 4. A, crystal structure of PM III complexed with pepstatin. Shown is a ribbon structure (blue) with Asp215 and His32 highlighted in yellow with red and blue
heteroatoms. Pepstatin is in green with red oxygens. The figure was constructed from PDB entry 3FNT. B, crystal structure of PM II (blue) with the B helix of the
hemoglobin  chain modeled in orange. The 33–34 cleavage site is green; the helix-interacting loop is magenta; from PDB entry 1PSE. Created using PyMOL
Molecular Graphics System, Version 2.3.
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apoenzyme structure had active site zinc (67), whereas it is the
monomer that is active (70). A proposal was put forth that
Asp215 acts as an acid as well as a base, but this model was based
on a profound stabilization (several orders of magnitude) by
His32 (75). Perhaps a different residue could be the stabilizer;
Lys78 has been suggested (73). Weighing on this debate is the
fact that the properties of native enzyme and the recombinant
enzyme used for mutagenesis studies are very different. PM III
was originally isolated from digestive vacuoles, had a sharp pH
optimum of 5.5, and was well-inhibited by pepstatin (5). Three
different isolation procedures gave similar results, and there
was no detectable contamination by other plasmepsins (al-
though trace contamination by a plasmepsin or another prote-
ase cannot be completely excluded). Recombinant protein
expressed in Escherichia coli had similar properties (76). Later,
recombinant protein was again expressed in E. coli for analysis
of site-directed mutants mentioned above but had a broad pH
optimum from 5 to 8.5, was poorly inhibited by pepstatin, and
was potently inhibited by phenylmethylsulfonyl fluoride (73). A
H215A mutant had no activity, but the S35A and H32A
mutants were similar to WT. It is hard to reconcile these later
results with the earlier data, unless there was a contaminating
activity present in some of the samples, perhaps from the
enterokinase used to generate mature recombinant enzyme.
The existing data do not yet form a coherent picture of the
mechanism of action of this unusual aspartic protease ortholog.
Specificity
An extensive series of studies has assessed specificity of
cleavage of hemoglobin or synthetic peptides using native and
recombinant digestive vacuole plasmepsins. The four P. falcip-
arum enzymes and the single enzyme from the three other
human parasite species (Plasmodium ovale, Plasmodium vivax,
and Plasmodium malariae) as well as enzyme from rodent spe-
cies (P. berghei and Plasmodium chabaudi) have been studied
(4 – 6, 77–90). All four P. falciparum enzymes are capable of
degrading hemoglobin and function at the acidic pH of the
digestive vacuole (5). Other degradative proteases such as
cathepsin E are not able to degrade native hemoglobin, so this is
a special property of the digestive vacuole plasmepsins (91).
There are minor differences between species, but activity on
synthetic peptide libraries shows a general preference for large
hydrophobic residues proximal to the cleavage site on the P
(N-terminal) and P (C-terminal) sides, especially at the P1 and
P3 positions, with somewhat broader tolerance at P1 and P3
and wide latitude at P2 and P2. On native hemoglobin, time
course studies using native PM I and PM II revealed an initial
cleavage of hemoglobin (22 tetramer) on the  chain between
Phe33 and Leu34 (1, 36). Proteolysis proceeded with cleavages at
a number of sites on both chains. Specificity of cleavage corre-
lated well with the data just mentioned for synthetic peptides.
Experiments using peptides corresponding to the scissile -he-
lix (helix B) revealed enhanced cleavage by PM II when the helix
was extended N-terminally and could then interact with a loop
on the PM II molecule (91). A model was put forth wherein the
plasmepsin recognizes the beginning of the B helix on the 
chain of hemoglobin and perches, waiting for the helix to
breathe. The B helix is the weakest link on the protein because
it has two helix-disrupting glycines. The protease is in position
to cleave the 33–34 peptide bond as soon as the helix opens,
helping unravel the tightly wound hemoglobin molecule so that
further proteolysis can proceed (Fig. 4B).
Biosynthesis
Biosynthesis of digestive vacuole plasmepsins follows a cir-
cuitous route. The enzymes are made as transmembrane zymo-
gens that traverse the secretory system, reach the parasite sur-
face, are internalized via the cytostome along with their
substrate hemoglobin, get delivered to the digestive vacuole
membrane, and are then cleaved, releasing the mature enzyme
into the vacuolar lumen (92–94) (Fig. 3C).
Maturation is carried out by the digestive vacuole cysteine
proteases falcipain-2 and -3 (49). If those enzymes are inhibited,
plasmepsin autoprocessing takes place, albeit at a slower rate
and at a site 1 amino acid upstream from the normal cleavage
site. Structures of P. falciparum PM II, PM III, and PM IV
proenzymes as well as those of P. vivax PM IV have been solved
(63, 95–97). The proenzyme of each is inactive because the
propiece pushes apart the N- and C-terminal lobes of the pro-
tease, keeping the catalytic residues too far apart for activity.
This differs from mammalian aspartic protease zymogens, for
which the propiece binds to the substrate cleft to maintain inac-
tivity until pH-dependent autoactivation can take place.
Key questions
• What is the mechanism of PM III? Is His32 involved in
catalysis? Is PM III even an active enzyme?
• Systems biology of hemoglobin degradation: How do
cleavages made by each plasmepsin and by other proteases
synergize? Why maintain four plasmepsins in P. falcipa-
rum? Why do some parasites amplify the digestive vacuole
plasmepsin gene region even further?
• When is heme released during hemoglobin proteolysis,
and how is this orchestrated with hemozoin formation?
Effector protein export: Plasmepsin V
After invasion, the parasite exports hundreds of proteins into
the host RBC. These exported effectors enact a dramatic pro-
gram of host modification, reconstituting a complex trafficking
system in the RBC cytosol and altering the host cell’s rigidity,
nutrient permeability, and endothelial binding properties (98,
99). A significant portion of this export program appears dedi-
cated to trafficking families of variable membrane adhesins to
the RBC surface, creating adhesin-rich protrusions called
“knobs” that mediate binding to the vascular endothelium (Fig.
5) (100). In P. falciparum, around 400 predicted gene products
are annotated as likely to be exported (101, 102). Nearly 200
belong to three families of membrane adhesins (120 rifins, 50
PfEMP1s, and 30 stevors) (101, 103). Many of the remaining
predicted proteins have no clear function and no homology to
genes outside Plasmodium. We are still just beginning to
understand the mechanisms by which Plasmodium manipu-
lates its host through its exported proteins.
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Initial evidence of aspartic proteases acting on processes
other than hemoglobin degradation came nearly 2 decades ago,
when antibodies raised against newly annotated aspartic pro-
teases labeled parasites outside the digestive vacuole (104). PM
V was characterized as a constitutively expressed endoplasmic
reticulum (ER)-resident integral membrane protein (105). In
2004, the Haldar and Cowman groups independently discov-
ered that many proteins destined for export contain a pentam-
eric amino acid motif 15–30 amino acids downstream from
the signal sequence, termed the Plasmodium export element
(PEXEL) with the consensus sequence RXLX(E/Q/D) (106,
107). This element was shown to be necessary and sufficient to
export fluorescent reporters. In 2008, Chang et al. (108)
reported that exported proteins are cleaved in the ER, after the
conserved Leu in the PEXEL sequence. The advent of tools for
reverse genetics in P. falciparum enabled the assignment of the
PEXEL-processing function to PM V (109, 110). Development
of peptidomimetic inhibitors of PM V has driven further dis-
covery, validating PM V as essential for parasite survival in
RBCs during the asexual cycle and gametocytogenesis (111–
113). In addition to uncovering novel parasite biology, these
inhibitors have enabled the determination of a high-resolution
PM V structure, opening the door to biochemical and pharma-
cological investigation of this essential enzyme (114). A number
of tools have now been turned toward the study of PM V,
including inducible Di-Cre excision (115) and post-transcrip-
tional depletion (111, 116, 117), as well as expression, purifica-
tion, and activity assessment of PM V expressed from E. coli
(110, 118–121), from insect cells (114), and from parasite cul-
ture (109, 110). This has enabled rapid progress in our knowl-
edge of this enzyme and its development as a potential antima-
larial target.
Function
PEXEL-containing proteins are translated into the ER,
immediately processed by PM V after the PEXEL Leu, and then
acetylated at the new N terminus by an unknown N-acetyl-
transferase (108 –110, 122, 123). Preventing PEXEL processing
by mutating PEXEL or depleting/inhibiting PM V blocks pro-
tein export, indicating that PM V serves as a gatekeeper for the
export pathway (106, 107, 111, 117). Processed PEXEL proteins
are secreted into the parasitophorous vacuole and then
exported across the vacuolar membrane into the host cell via
the Plasmodium translocon for exported proteins (PTEX)
(124 –127) (Fig. 5). A number of proteins lack PEXEL yet are
still exported, termed PEXEL-negative exported proteins
(PNEPs). Their N termini are believed to confer export compe-
tency similarly to that of the mature PEXEL N terminus (128).
Most known PNEPs are involved in trafficking adhesins to the
RBC surface or are adhesins themselves.
PM V is not the only gatekeeper to protein export; several
mutated PEXEL reporters are correctly cleaved by PM V but
still retained in the parasitophorous vacuole (101, 123). Two
non-mutually exclusive models have been put forward to
explain this. First, export-destined proteins may contain traf-
ficking information in addition to PEXEL that targets them for
export. This information would have to be C-terminal to
PEXEL, as the N-terminal sequence is removed by PM V.
Exported reporter studies have greatly limited the possible
locations of such information. The N terminus of PEXEL pro-
teins, containing the PEXEL motif followed by just 11 amino
acids, supports export of a GFP fusion (106, 107). Following
PEXEL cleavage, the only detectable sequence conservation is
the P2 residue (largely restricted to Gln, Glu, or Asp). Residues
beyond P2 are important for export, as an inserted PEXEL was
not sufficient to re-target the normally vacuole-resident SERA5
to the RBC, but if the subsequent 18 amino acids from the
PEXEL protein PfEMP3 were added, export was restored (101).
However, the properties of these sequences that support export
have remained elusive; they have no obvious conserved
sequence, structure, or biochemical properties; and Boddey et
al. (101) reported the surprising finding that even replacing the
post-P2 amino acids with all Ala supports protein export, leav-
ing us to wonder what signaling information this sequence
could contain. A variant of this model would be that secreted
proteins bind HSP101 and get exported by default, unless they
are too tightly folded (129) or contain an N-terminal sequence
that prevents chaperone recognition.
The second model posits that following PEXEL cleavage, PM
V hands off export-destined cargo to an ER chaperone that
ushers it through the export pathway (109). In this model, PM V
is required not just for cleavage, but also for some downstream
Figure 5. Biosynthesis and trafficking of exported proteins. Proteins are
synthesized in the ER and traverse the secretory system (green) to the parasi-
tophorous vacuole (blue), where they are recognized by the PTEX translocon
and exported into the RBC (pink). In the RBC, effectors can be soluble, can
reside in the Golgi-like Maurer’s clefts that are established by the parasite in
the host cell, can be vesicular, or can go to the RBC surface, forming nutrient
acquisition channels (PSAC) or clustering variant surface cytoadhesins in
knobs at the RBC surface.
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steps. Tests of this model were attempted with constructs that
would create a post-PEXEL N terminus independent of PM V
using either an engineered signal peptidase or a fused viral pro-
tease; these gave discordant results, with the signal peptidase-
generated N terminus unable to support export, whereas the
viral protease-generated N terminus did support export (110,
130).
Another avenue for elucidating the post-PM V path is to
determine its interacting partners, a task that was carefully
undertaken by Danushka et al. (131). They found that PM V
interacts with a noncatalytic component of the signal peptidase
complex SPC25 and, if cross-linked, with the ER translocon
Sec61, its accessory proteins for post-translational import
Sec62/63, as well as signal peptidase. They posited that secre-
tory proteins follow one of two distinct paths: either they are
cleaved by the canonical signal peptidase complex, or they are
recognized and cleaved by a distinct signal-processing complex
consisting of PM V and SPC25 (131) (Fig. 6). Perhaps there are
chaperones that recognize this complex selectively, although
their identity is not apparent at this time. A variant of the
chaperone hand-off model is that PM V could be in a subre-
gion of the ER with a direct route to the PTEX translocon at
the PVM (110, 132). Subregions of the PVM have recently
been described, with each region hosting distinct secretory
proteins (133, 134). However, there is no information yet
about whether these PVM subregions are fed by distinct
regions of the ER.
There is some evidence that PM V additionally functions as a
secretory maturase for dense granule proteins. Dense granules
are small secretory vesicles that discharge shortly after parasite
invasion into the parasitophorous vacuole surrounding the par-
asite. In addition to the canonical PEXEL, PM V cleaves the
“relaxed PEXEL” (RXLXXE) of the dense granule protein RESA
(101, 117). Following PEXEL cleavage, RESA is diverted to the
dense granules of the forming daughter merozoites. When
these merozoites re-invade new RBCs, RESA is secreted into
the vacuolar lumen and rapidly exported via PTEX into the host
cell (124, 125). Inhibition of PM V shortly before egress is rap-
idly deleterious in newly invaded ring-stage parasites (117).
RESA itself is nonessential, and whether PM V cleaves addi-
tional dense granule proteins is not yet clear. In T. gondii, the
PM V ortholog ASP5 cleaves dense granule proteins at a
PEXEL-like motif (135–137). When ASP5 processing is
blocked, substrates still traffic to the dense granules but are
unable to fulfill their roles in modifying the parasitophorous
vacuole or host cell (136). If PM V does act as a dense granule
protein maturase in both Toxoplasma and Plasmodium, per-
haps this is its ancestral function, a concept that would be espe-
cially interesting given recent findings on the translocon,
PTEX. This complex is made up of three core components: an
AAA-ATPase, Hsp101; a channel-forming protein, Exp2; and
an adaptor protein, PTEX150 (126). Hsp101 is a ubiquitous
chaperone that has been co-opted by Plasmodium to unfold
and thread proteins through the translocon. Exp2, in Plasmo-
dium and Toxoplasma, forms a nutrient pore to get essential
substances such as glucose and amino acids from the host cell
(138, 139). This protein has also been deployed by Plasmodium
for a second function—protein export. To dock Hsp101 to the
Exp2 pore for protein export, the organism has come up with a
novel adapter, PTEX150 (127). Thus, we suggest that Plasmo-
dium has cobbled together a protein export system from mostly
preexisting components, and further, it has recruited another
preexisting protein, PM V, to prepare proteins for export. It is
not at all clear why most exported proteins need to be made as
preproteins and processed by PM V co-translationally unless
the cleavage motif (PEXEL) is an important component of the
export recognition system.
Specificity
Unlike the digestive vacuole proteases, PM V has a highly
specific recognition sequence, cleaving only after the conserved
Leu of the consensus PEXEL sequence RXLX(E/Q/D) (108, 122,
123). Mutation of the highly conserved PEXEL residue P1 or P3
ablates cleavage (with the notable exception of P1 Ile, which can
inconsistently support some PM V cleavage) (101, 106, 107,
140). PM V does not cleave the PNEPs SBP1, PfEMP1, and
REX2 (101) or a fluorogenic globin-derived peptide cleaved by
PM I–IV (105). Functional PEXELs are found 15–30 amino
acids downstream of the signal sequence (141); however,
whether this location is required for PM V cleavage has not
been reported.
Figure 6. Model for signal processing in the ER. Secretory proteins are
cleaved immediately after translation either by the canonical signal pepti-
dase (SPC21) complex (left) or a noncanonical PM V–processing complex
(right). NAT, putative N-acetyltransferase.
Figure 7. Crystal structure of PM V with the inhibitor WEHI-842 bound
(green). Highlighted are the flap over the active site (magenta), nepenthesin
loop (yellow, with Cys-Cys bonds in red), and helix-turn-helix (orange); from
PDB entry 4ZL4.
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The structure of the P. vivax PM V bound to a peptidomi-
metic inhibitor has been determined and reveals that PM V
largely resembles the digestive vacuole plasmepsins, with a few
notable differences (114) (Fig. 7). Like PM I-IV, PM V is pro-
duced with a poorly conserved N-terminal extension specu-
lated to be a self-inhibiting prodomain. However, processing of
PM V has not been detected (105), and the full-length recom-
binant protein has been reported to be active (118, 119). As in
other plasmepsins, the PM V active site is covered by a flap that
may serve to regulate substrate access. The PM V flap is several
amino acids longer than the analogous region of the digestive
vacuole plasmepsins, a difference that could perhaps underlie
PM V’s unique substrate specificity. Along the flap (but not
predicted to contact the substrate) is an unpaired Cys, which
has been implicated in PM V’s sensitivity to Hg2 (118, 120,
121). Connected directly to the flap is an insert made up of two
cysteine pairs folded into a cloverleaf-like structure called a
“nepenthesin insert,” which it shares with Nep1 from the
pitcher plant Nepenthesia. The nepenthesin insert is present in
PM V across the genus, but absent from other plasmepsins. Its
location adjoined to the flap over the active site tempts us to
speculate that the nepenthesin insert may respond to some
environmental condition or binding partner and regulate
access to the active site. Alternatively, the nepenthesin insert
could be a set distance from the active site and be involved in
measuring distance from the N-end of potential substrates
(142). No clear hint comes from its ortholog Nep1, a broad-
substrate digestive protease present in the low pH of the pitcher
plant lumen (143). Another unusual feature is a helix-turn-helix
motif, again not present in other plasmepsins. Whereas this is
often a nucleic acid-interacting motif, it is not clear what pur-
pose such a motif might have in the ER lumen, where all but the
nonessential C-terminal tail of PM V is found (109, 144). Pro-
jecting away from the active site of the enzyme is a poorly struc-
tured insert whose length and sequence varies among different
Plasmodium species and isolates from different regions (145,
146); mutagenesis studies on recombinant enzyme have not yet
revealed a function for this structure (146). Further work has
the potential to both uncover novel parasite biology and also
unearth secrets of biochemistry broadly applicable to other
enzymes outside of Plasmodium.
Key questions
• What do signature features of PM V do (helix-turn-helix
motif, nepenthesin loop, unpaired cysteine in the flap)?
• What is the basis of exported protein targeting, and how is
PM V involved? Is N-acetylation a required part of this,
and is it coordinated with PM V action?
• What are the essential PM V substrates required for para-
sitophorous vacuole establishment?
Transmission-stage plasmepsins: Plasmepsins VI, VII,
and VIII
PM VI, VII, and VIII are expressed only in transmission-stage
parasites and have roles in midgut sporozoite development and
function (104). They have been studied mostly in the rodent
malaria parasite P. berghei, where each has been disrupted with
no effect in the RBC cycle. PM VI knockout parasites produce
oocysts that fail to develop into sporozoites, resulting in a trans-
mission block (147). PM VII can be detected in the cytoplasm of
P. falciparum zygotes and ookinetes, but its function is not
known (148). The protein is not present in P. falciparum game-
tocytes, suggesting that it is produced after fertilization. Knock-
out has no effect on any stage of the P. berghei life cycle (149).
PM VIII knockout parasites form oocysts in the mosquito
midgut (150). However, there is a drastic decrease in the num-
ber of salivary gland and hemolymph sporozoites when PM VIII
is absent, due to a defect in egress from oocysts. The few sporo-
zoites produced have a defect in gliding motility. Consequently,
transmission of these parasites to the host is blocked. The
egress phenotype mirrors that seen with PM X in intraerythro-
cytic parasites (see below), but mechanistic details for PM VIII
function remain to be elucidated. More work is needed to
understand the function of these important enzymes.
Key questions
• What are the specific roles and substrates of these
proteases?
• Do the inhibitors being developed against other plas-
mepsins also target the transmission-stage plasmepsins?
• What is the role of other plasmepsins, such as PM X, in the
transmission stages?
Egress/invasion plasmepsins: Plasmepsins IX and X
An obvious consequence of the malaria parasite’s intraeryth-
rocytic lifestyle is that it needs to get into the host cell and, when
it is finished replicating and dividing, needs to get back out (Fig.
8A). Invasion is a multistep process (151, 152) involving initial
low-affinity recognition of the red blood cell by the parasite,
reorientation of the invasive merozoite, and discharge of secre-
tory organelles. This allows high-affinity binding to erythrocyte
surface proteins and to parasite proteins that the organism has
secreted onto the host cell membrane. This is followed by
erythrocyte cytoskeletal reorganization and signaling cascades,
tight junction formation, actin-mediated entry, and finally
resealing once inside. The whole invasion process takes less
than a minute. Egress is also a complex phenomenon (153–
155). The parasite must porate and disrupt the surrounding
parasitophorous vacuolar membrane, disassemble the host
cell cytoskeleton, porate, and finally rupture the erythrocyte
membrane, which it does explosively, releasing new infective
merozoites into the circulation. The egress process takes
about 10 min. Proteases play key roles in egress and invasion;
in invasion, proteolytic processing is essential for invasion
protein function; in egress, there is a proteolytic cascade,
triggered by the cGMP-dependent discharge of proteases
into the parasitophorous vacuole (154). Recent evidence
suggests that aspartic proteases play important roles in both
entry and exit from the erythrocyte.
PM IX is expressed in late-stage schizonts and is localized to
rhoptries (Fig. 8B), secretory organelles that contain adhesins
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for erythrocyte invasion and proteins for setting up the PVM
upon invasion (156). This organelle is highly segregated, with
the invasion ligands at the apical end (neck) and other proteins
at the basal end (bulb). Upon depletion/disruption of P. falcip-
arum PM IX, invasion of red blood cells is severely compro-
mised (156, 157). Depletion/disruption of PM IX also blocks
cleavage of the rhoptry-associated protein 1 (RAP1) and the
apical sushi protein (ASP). Peptides corresponding to the cleav-
age sites of both proteins are cleaved by recombinant PM IX.
The activity was observed at pH 6.4 (157). RON3, a rhoptry
protein inserted into the PVM during or just after invasion, is
also thought to be a PM IX substrate from inhibitor studies
(158). Rhoptry morphogenesis and attachment defects were
observed in the PM IX-depleted strain (156). These defects pre-
sumably explain the invasion phenotype observed. The sub-
strates of PM IX responsible for the phenotype are still not
known, because RAP1 is not essential (159) and ASP is pre-
dicted to be nonessential by a piggy bac transposon mutagene-
sis screen (160). Maturation of PM IX appears to be autocata-
lytic (158).
PM X is involved in both egress and invasion (156 –158). In
asexual P. falciparum parasites, PM X is localized to small oval-
shaped vesicles called exonemes (156). The other protein that
has been localized to this organelle is the serine protease sub-
tilisin-like protease 1 (SUB1). PM X processes SUB1 to activate
it. Knockdown or chemical inhibition of PM X results in the
accumulation of SUB1 precursor (156 –158). Mature SUB1 is
required for the degradation of both the parasitophorous vac-
uole and red cell membranes to allow dissemination of mero-
zoites from a mother schizont. To initiate the egress cascade,
SUB1 activates cysteine proteases called SERAs and merozoite
surface proteins called MSPs (154). Full block of PM X traps
parasites within the PVM, whereas partial block allows egress
from this membrane but prevents escape from the RBC mem-
brane. Presumably, a higher level of activated SUB1 is required
for its effects on the erythrocyte. PM X also processes the sur-
face adhesin sheddase SUB2 as well as erythrocyte binding-like
(EBL) and Rh family members that are all involved in invasion
(158). In sexual stages of P. falciparum, PM X is expressed in
gametes, zygotes, and ookinetes and in P. berghei, it is impli-
cated by inhibitor studies in egress from gametocytes and mos-
quito midgut invasion (148, 157). PM X processes the midgut
invasion protein cell-traversal protein for ookinetes and sporo-
zoites (CelTOS) (157). Inhibitors also prevent progression from
the liver to erythrocytes, although different compounds either
block merosome formation (hence egress of schizonts in hepa-
tocytes (157)) or have an effect on merozoite competence (158).
It is worth noting that compounds used in these studies inhibit
both PM IX and PM X. PM IX is not expressed in liver or
sexual stages, however, suggesting that action may be spe-
cific to PM X in these portions of the life cycle, although
some effects through action on another aspartic protease
may be suggested by the fact that different small molecules
have been reported to have somewhat different effects on
mosquito and liver-stage parasites.
Recombinant PM X is active at pH 5.5 and can cleave a vari-
ety of synthetic peptide substrates, including ones based on
SUB1, EBA-175, EBA-181, and Rh2 (156 –158). It has a strong
preference for cleavage between two hydrophobic residues, not
dissimilar from the digestive vacuole plasmepsins, and prefers a
polar P2 residue and Glu, Gln, or Asp for P2 (158). PM X can
cleave PM IX substrates, suggesting overlapping specificity
(158). PM X is autocatalytic, but in parasites not all of the PM X
gets processed; they retain some as proenzyme (66 kDa) or as
active 51- and 44-kDa versions (156 –158). An ER calcium-
binding protein called PfERC is required for PM X maturation
in an unknown fashion (161).
In Toxoplasma gondii, one aspartic protease called ASP3 is
closely related to both PM IX and PM X (9). It is localized in an
endosomal compartment (post-Golgi). This protein processes
microneme and rhoptry proteins and is implicated in egress
and invasion and hence is thought of as a PM IX and PM X
chimera (162). Mutations in the conserved Phe344 confer resis-
tance to the small-molecule inhibitor 49c in cultured Toxo-
Figure 8. Plasmodium invasion and egress. A, an infective merozoite (top
left) attaches to an RBC, reorients so that its apical end is in contact with the
host cell, and invades. It develops, replicates, and divides, forming a schizont
(bottom right). When ready to egress, it disrupts the PVM and then the RBC
membrane, and finally merozoites rupture out of the RBC explosively (bottom
left). B, schematic of a merozoite, showing secretory organelles whose func-
tion is influenced by plasmepsins. Exonemes discharge to initiate egress.
Then micronemes discharge to secrete RBC adhesion ligands onto the cell
surface. Next, rhoptries discharge to prepare the parasite and host cell for
invasion and to condition the PVM. Finally, dense granules discharge to effect
maturation of the parasitophorous vacuole.
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plasma and for isolated ASP3, PM IX, or PM X (163). The
cleavage sites for ASP3 substrates are similar to the peptide
cleavage sites for the PM IX and PM X that were tested, adding
to the concept of their relatedness and similar roles in the two
organisms. PM V, IX, and X all share a function as secretory
organelle protein maturases (Fig. 8B).
Key questions
• What are the key substrates of PM IX required for rhoptry
morphogenesis?
• How does PM X cleave and activate the SUB1 precursor
that is bound to its propiece?
• Where does PM X interact with and process some
microneme and rhoptry proteins? It has only been found
in exonemes thus far.
Other aspartic proteases
Four other putative aspartic proteases are encoded in the
Plasmodium genome but were not appreciated when the plas-
mepsins were named (164). MiGS is most homologous to PM V
but is expressed in male gametocytes and microgametes (165,
166). It appears to play a role in formation of the secretory
osmiophilic bodies of male gametocytes. After secretion onto
the surface, it also plays a role in exflagellation of male microg-
ametes that go on to fertilize the female gametes. Like the other
plasmepsins, it is predicted to have a classical pepsin-like fold;
however, one of the catalytic sites has clearly undergone sub-
stantial mutation, with the conserved DTGS mutated to LTNS.
Whether MiGS folds in an unexpected way to bring another
catalytic residue into the active site, acts as a homodimer, or
acts as a pseudoprotease is unclear.
Ddi1 (DNA damage-inducible protease 1) is another aspartic
protease with a Plasmodium ortholog. In other eukaryotes, it is
important for the cell cycle through ubiquitin/proteasome
interactions (167). It has only one catalytic aspartate and
homodimerizes to form the active enzyme. In malaria parasites,
all that is known is that its gene is refractory to knockout in
P. berghei and P. falciparum (160, 168, 169).
SPP is an intramembrane aspartic protease that processes
signal peptides after release from secretory proteins in the ER.
Early reports based on antibody and inhibitor studies suggested
that the Plasmodium ortholog of SPP might be a micronemal
protein involved in invasion (170, 171). Further reports, how-
ever, instead localized this protein to the ER and demonstrated
roles in signal peptide proteolysis and ER stress responses
(172–174). More detailed cellular analysis of SPP-selective
inhibitor treatment showed inhibition of intraerythrocytic par-
asite development rather than invasion (172). Heterologous
expression studies have confirmed the ability to cleave
intramembrane signal peptides (173, 175, 176). Potent SPP
inhibitors that kill cultured intraerythrocytic parasites (171–
173, 177) and also block liver-stage development (173, 178)
have been described. SPP appears to be an attractive drug
target.
Finally, a gene present on chromosome 14 (PF3D7_1465600)
next to PM VIII and annotated as an aspartic protease (164) has
very distant homology to PM VIII, but the predicted protein is
missing both catalytic motifs and is unlikely to be an active
protease. It is expressed most highly in male gametocytes and
may also be expressed in asexual parasites and other life-cycle
stages (179). The gene is predicted to be essential in P. falcipa-
rum but not in P. berghei from genome-scale mutational anal-
yses (160, 168). Its function is completely unknown.
Key questions
• How does MiGS work in exflagellation? Is it an active
enzyme? What are its substrates?
• What is the role of Ddi1 in the parasite? What are associ-
ated proteins and substrates?
• Can selective SPP inhibitors be developed? What is the
role of SPP in the ER stress response?
Plasmepsins as drug targets
Thousands of inhibitors have been designed against plas-
mepsins. Additionally, clinically used HIV protease inhibi-
tors such as lopinavir have been investigated in detail,
although their clinical antimalarial efficacy is likely to be
marginal. The inhibitor literature has been reviewed else-
where (8, 180, 181) and is beyond the scope of this article.
Here, we will instead focus on implications of the biology of
plasmepsins for drug development.
Digestive vacuole plasmepsins play an important role in
hemoglobin degradation. Knockout lines are markedly im-
paired in growth both in culture (P. falciparum) (42) and in vivo
(P. berghei- rodent model) (43, 44). In fact, the attenuated
P. berghei are cleared and can protect from subsequent chal-
lenge with heterologous parasites. That being said, knockout
parasites are still viable, and an anti-digestive vacuole plasmep-
sin drug would need a very long half-life to suppress growth
over multiple cycles for parasite clearance. It is unlikely that a
digestive vacuole plasmepsin-specific agent will come to frui-
tion, although a compound that blocked digestive vacuole plas-
mepsins in addition to an essential plasmepsin (CWHM-117 is
an example (156)) would likely get an efficacy boost from its
action on hemoglobin degradation.
PM V is another interesting enzyme to consider as a target.
The process of protein export is essential (124, 125, 138), as
presumably is dense granule secretion that helps form the para-
sitophorous vacuole after invasion, in which PM V likely plays a
role (117). Blocking PM V could potentially hit the parasite at
two different points in its developmental cycle, which is an
advantage for treating an infection that can be asynchronous.
Tempering enthusiasm for this target is the observation that
PM V must be knocked down nearly completely to have any
effect on parasite viability. The implication is that a drug would
have to have exceptional potency to be effective. Current rec-
ommended EC50 values for parasite killing by candidate com-
pounds are in the low nanomolar range. A compound would
likely have to have a mid-picomolar ki for PM V to achieve
efficacy—not impossible, but a very high bar.
Plasmepsin VI, VII, and VIII are potential drug targets for
insect stages of the parasite. A drug against an enzyme in these
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stages would not cure a patient but could prevent transmission
of the disease. Dosing patients to get a curative concentration in
the mosquito is a potential hurdle. Not enough is known about
these enzymes to have a clear idea how to move forward. PM
VII appears to be dispensable and therefore would be low on the
list.
PM IX is a candidate drug target. It is essential for blood-
stage parasites (156, 157) and is inhibited by the small-molecule
inhibitors 49c and WM382 (157, 158), although both com-
pounds are also potent against PM X. PM X is also essential for
blood-stage parasites and can be potently blocked by the dual-
inhibitory compounds mentioned above, as well as by amino-
hydantoins (156 –158). Each of these chemotypes is active in
vivo using rodent malaria models, and 49c and WM382 also
have been shown to interrupt transmission to mosquitos as well
as egress from hepatocytes. The extra-erythrocytic phenotypes
are likely due to a block of PM X, although an important role for
the inhibition of other plasmepsins such as PM VI–VIII cannot
be excluded. Dual inhibition of PM IX and X or of PM X and an
insect-stage PM would be a bonus for an antimalarial because of
heightened difficulty in selecting resistance or ability to treat
more than one stage (157, 158). However, keeping a drug devel-
opment program on-target for two different enzymes while
avoiding inhibition of host orthologs such as cathepsin D is a
challenging task (182, 183). Inhibition of PM X may be enough
to hit multiple life cycle stages by itself. Drug development for
PM X is proceeding at a rapid pace (158) (https://www.mmv.
org/research-development/mmv-supported-projects).
Key questions
• HIV protease inhibitors like lopinavir kill malaria parasites
in culture. What is their killing target? The digestive vac-
uole plasmepsins, Ddi1, SPP, and hexose transporter
PfHT1 have all been proposed (169, 184–188).
• Do PM X inhibitors work in mosquito stages by blocking
PM X, and/or do they target other enzymes, such as MiGS
or PM VI–VIII?
• Will a drug against a target that is active during just a few
hours of the life cycle show sustained efficacy?
• Is hemoglobin digestion a viable target?
Conclusions
Plasmepsins participate throughout the complex biology of
the malaria parasite (Table 1). The digestive vacuole plas-
mepsins are the most extensively studied, and we have a rea-
sonable picture of their biosynthesis and roles in hemoglobin
degradation. We do not yet understand the mechanism of PM
III, with its histidine instead of a canonical aspartate. Plasmep-
sin V is the next best-studied plasmepsin. Its role in exported
effector protein processing is fairly clear, but its function in
dense granule protein processing is not well-established. The
protein has a number of unusual domains whose functions are
not clear at this time. Plasmepsins VI–VIII as well as the PM V
paralog MiGS play roles in the insect stages; PM X may as well.
Studies of these protease activities in the mosquito are just
beginning. PM IX and PM X have defined roles in erythrocytic
invasion and egress, but their enzymology is not yet defined.
Many of these enzymes afford opportunities for antimalarial
drug discovery, and we can look forward to exciting new drug
candidates in the not too distant future.
EuPathDB Accession numbers
Plasmepsins: I (PF3D7_1407900), II (PF3D7_1408000), III
(PF3D7_1408100), IV (PF3D7_1407800, PBANKA_1034400), V
(PF3D7_1323500), VI (PF3D7_0311700), VII (PF3D7_1033800),
VIII (PF3D7_1465700), IX (PF3D7_1430200), X (PF3D7_
0808200); other proteases: MiGS (PF3D7_1234400), DDI1
(PF3D7_1409300), SPP (PF3D7_1457000), falcipain 2 (PF3D7_
1115700), falcipain 3 (PF3D7_1115400), DPAP1 (PF3D7_
1116700), aminopeptidase P (PF3D7_1454400), amino-
peptidase M1 (PF3D7_1311800), SUB1 (PF3D7_0507500),
SUB2 (PF3D7_1136900), TgAsp1 (TGME49_201840), TgAsp2
(TGME49_262940), TgAsp3 (TGME49_246550), TgAsp4
(TGME49_209620), TgAsp5 (TGME49_242720), TgAsp6
(TGME49_272510); other proteins: HDP (PF3D7_1446800),
RAP1 (PF3D7_1410400), ASP (PF3D7_0405900), AMA1
(PF3D7_1133400).
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